Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling

Executive Summary

Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.

Advertisement

Related Content

Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Sanofi R&D Chief Zerhouni: How I'm Doing More With Less
Sanofi, Lonza JV Should Offer Pair Flexibility In Biologics Manufacturing
Stockwatch: Flat Is The New Black For Lilly And Sanofi
‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
Brandicourt reorganizes Sanofi

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel